Multi-tyrosine kinase inhibitor

DRUG CLASS:

Multi-tyrosine kinase inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

›

EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria Cancer Med - 5 days (New C3) anlotinib + sintilimab Sensitive : C2 Cancer Med - 5d	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria Cancer Med - 5 days anlotinib + sintilimab Sensitive : C2 Cancer Med - 5 days - (New C3)
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	anlotinib Sensitive: C2 – Inclusion Criteria Int J Gen Med - 1 week (New C3) anlotinib Sensitive : C2 Int J Gen Med - 1wk	anlotinib Sensitive: C2 – Inclusion Criteria Int J Gen Med - 1 week anlotinib Sensitive : C2 Int J Gen Med - 1 week - (New C3)
ALK rearrangement	Non Small Cell Lung Cancer	ALK rearrangement	Non Small Cell Lung Cancer	gilteritinib Sensitive: D – Preclinical Cancer Sci - 1 week (New D) gilteritinib Sensitive : D Cancer Sci - 1wk	gilteritinib Sensitive: D – Preclinical Cancer Sci - 1 week gilteritinib Sensitive : D Cancer Sci - 1 week - (New D)
RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	RNASET2 overexpression	Clear Cell Renal Cell Carcinoma	midostaurin Sensitive: C3 – Early Trials BMC Cancer - 2 weeks (New C3) midostaurin Sensitive : C3 BMC Cancer - 2wk	midostaurin Sensitive: C3 – Early Trials BMC Cancer - 2 weeks midostaurin Sensitive : C3 BMC Cancer - 2 weeks - (New C3)
Low NLR	Renal Cell Carcinoma	Low NLR	Renal Cell Carcinoma	sorafenib Sensitive: C3 – Early Trials Cancer Control - 2 weeks (New C3) sorafenib Sensitive : C3 Cancer Control - 2wk	sorafenib Sensitive: C3 – Early Trials Cancer Control - 2 weeks sorafenib Sensitive : C3 Cancer Control - 2 weeks - (New C3)
Low MLR	Renal Cell Carcinoma	Low MLR	Renal Cell Carcinoma	sorafenib Sensitive: C3 – Early Trials Cancer Control - 2 weeks (New C3) sorafenib Sensitive : C3 Cancer Control - 2wk	sorafenib Sensitive: C3 – Early Trials Cancer Control - 2 weeks sorafenib Sensitive : C3 Cancer Control - 2 weeks - (New C3)
BCR-ABL1 fusion	Acute Lymphocytic Leukemia	BCR-ABL1 fusion	Acute Lymphocytic Leukemia	ponatinib Sensitive: A1 - Approval SOHO 2023 - 3 weeks (New B) ponatinib Sensitive : A1 SOHO 2023 - 3wk	ponatinib Sensitive: A1 - Approval SOHO 2023 - 3 weeks ponatinib Sensitive : A1 SOHO 2023 - 3 weeks - (New B)
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	sorafenib Sensitive: A2 - Guideline Am J Hematol - 3 weeks (New C3) sorafenib Sensitive : A2 Am J Hematol - 3wk	sorafenib Sensitive: A2 - Guideline Am J Hematol - 3 weeks sorafenib Sensitive : A2 Am J Hematol - 3 weeks - (New C3)
NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	TPX-0005 Sensitive: B - Late Trials Zai Lab Press Release - 3 weeks (New C3) TPX-0005 Sensitive : B Zai Lab Press Release - 3wk	TPX-0005 Sensitive: B - Late Trials Zai Lab Press Release - 3 weeks TPX-0005 Sensitive : B Zai Lab Press Release - 3 weeks - (New C3)
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	TPX-0005 Sensitive: B - Late Trials Zai Lab Press Release - 3 weeks (New C3) TPX-0005 Sensitive : B Zai Lab Press Release - 3wk	TPX-0005 Sensitive: B - Late Trials Zai Lab Press Release - 3 weeks TPX-0005 Sensitive : B Zai Lab Press Release - 3 weeks - (New C3)
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	TPX-0005 Sensitive: B - Late Trials Zai Lab Press Release - 3 weeks (New C3) TPX-0005 Sensitive : B Zai Lab Press Release - 3wk	TPX-0005 Sensitive: B - Late Trials Zai Lab Press Release - 3 weeks TPX-0005 Sensitive : B Zai Lab Press Release - 3 weeks - (New C3)
KIT mutation	Melanoma	KIT mutation	Melanoma	regorafenib Sensitive: C2 – Inclusion Criteria Eur J Cancer - 3 weeks (New C3) regorafenib Sensitive : C2 Eur J Cancer - 3wk	regorafenib Sensitive: C2 – Inclusion Criteria Eur J Cancer - 3 weeks regorafenib Sensitive : C2 Eur J Cancer - 3 weeks - (New C3)
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	nivolumab + regorafenib Sensitive: C3 – Early Trials Lancet - 3 weeks (New C3) nivolumab + regorafenib Sensitive : C3 Lancet - 3wk	nivolumab + regorafenib Sensitive: C3 – Early Trials Lancet - 3 weeks nivolumab + regorafenib Sensitive : C3 Lancet - 3 weeks - (New C3)
FLT3 mutation	Leukemia	FLT3 mutation	Leukemia	venetoclax + gilteritinib Sensitive: D – Preclinical SOHO 2023 - 3 weeks (New D) venetoclax + gilteritinib Sensitive : D SOHO 2023 - 3wk	venetoclax + gilteritinib Sensitive: D – Preclinical SOHO 2023 - 3 weeks venetoclax + gilteritinib Sensitive : D SOHO 2023 - 3 weeks - (New D)
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1	nivolumab + cabozantinib tablet Sensitive: A1 - Approval nivolumab + cabozantinib tablet Sensitive : A1
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : A1	gilteritinib Sensitive: A1 - Approval gilteritinib Sensitive : A1
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1	cabozantinib capsule Sensitive: A1 - Approval cabozantinib capsule Sensitive : A1
No biomarker	Thyroid Gland Carcinoma	No biomarker	Thyroid Gland Carcinoma	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : A1	midostaurin Sensitive: A1 - Approval midostaurin Sensitive : A1
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
BCR-ABL1 T315I	Acute Lymphocytic Leukemia	BCR-ABL1 T315I	Acute Lymphocytic Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
No biomarker	Thyroid Gland Hurthle Cell Carcinoma	No biomarker	Thyroid Gland Hurthle Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Follicular Carcinoma	No biomarker	Thyroid Gland Follicular Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Papillary Carcinoma	No biomarker	Thyroid Gland Papillary Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Thyroid Gland Medullary Carcinoma	No biomarker	Thyroid Gland Medullary Carcinoma	vandetanib Sensitive: A1 - Approval vandetanib Sensitive : A1	vandetanib Sensitive: A1 - Approval vandetanib Sensitive : A1
ABL1 T315I	Chronic Myeloid Leukemia	ABL1 T315I	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
Chr t(1;16)(q12;q11.2)	Chronic Myeloid Leukemia	Chr t(1;16)(q12;q11.2)	Chronic Myeloid Leukemia	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1	ponatinib Sensitive: A1 - Approval ponatinib Sensitive : A1
No biomarker	Lung Adenocarcinoma	No biomarker	Lung Adenocarcinoma	nintedanib Sensitive: A1 - Approval nintedanib Sensitive : A1	nintedanib Sensitive: A1 - Approval nintedanib Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1	sorafenib Sensitive: A1 - Approval sorafenib Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1
No biomarker	Colorectal Cancer	No biomarker	Colorectal Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
RAS wild-type	Colorectal Cancer	RAS wild-type	Colorectal Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
No biomarker	Osteosarcoma	No biomarker	Osteosarcoma	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2	regorafenib Sensitive: A2 - Guideline regorafenib Sensitive : A2
FLT3-TKD mutation	Acute Myelogenous Leukemia	FLT3-TKD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2
FLT3-ITD mutation	Acute Myelogenous Leukemia	FLT3-ITD mutation	Acute Myelogenous Leukemia	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2	midostaurin Sensitive: A2 - Guideline midostaurin Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2	sorafenib Sensitive: A2 - Guideline sorafenib Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2

Multi-tyrosine kinase inhibitor

Multi-tyrosine kinase inhibitor

Associations(834)

Associations
(834)